Related Experiment Videos
Peripheral blood stem cell autografts in CML
Leukemia & Lymphoma
|January 1, 1993
Summary
High-dose chemotherapy with autologous stem cell transplant for chronic myeloid leukemia (CML) may improve survival by reducing leukemia stem cells. However, most patients show return of Ph-positive cells post-transplant.
Area of Science:
- Hematology
- Oncology
- Stem Cell Transplantation
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome (Ph).
- High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (aHSCT) is a potential treatment strategy for CML in chronic phase.
- The theoretical benefit of aHSCT lies in reducing leukemic stem cells and re-establishing Ph-negative hematopoiesis.
Purpose of the Study:
- To evaluate the potential survival benefit of high-dose chemotherapy and aHSCT in chronic phase CML.
- To assess the impact of aHSCT on leukemic stem cell burden and Ph-negative hematopoiesis.
Main Methods:
- Patients with chronic phase CML received high-dose chemotherapy.
- Autologous hematopoietic stem cells were collected, cryopreserved, and reinfused post-chemotherapy.
Main Results:
- Some patients demonstrated partial Ph-negative hematopoiesis after aHSCT.
- The majority of patients exhibited entirely Ph-positive hematopoiesis one year post-aHSCT.
Conclusions:
- While aHSCT may offer theoretical survival advantages in CML, its clinical efficacy is limited by the frequent recurrence of Ph-positive hematopoiesis.
- Further research is needed to develop methods that promote sustained Ph-negative hematopoiesis after autografting to improve outcomes for CML patients.